Radiotherapy QA · Literature Radar
SBRT outcomes + protocol updates — per-site evidence for lung, liver, prostate, pancreas, spine, oligomets. Curated daily from Europe PMC (PubMed + PMC + preprints) and OpenAlex — free-full-text link on each open-access paper.
Sarkar B.
ObjectivesThis systematic narrative review evaluates the efficacy, safety, and future potential of stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (LAPC), particularly…
Xing S, Meyer S, Zhang L, Zhu L et al.
BackgroundSpinal nerve root ablation of 70-90 Gy with single fraction stereotactic radiosurgery (SRS) delivered in short partial arcs (30-60 degrees) is an emerging treatment for managing chronic thor…
Leblanc J, Terlizzi M, Lapierre A, Le Guévelou J.
Adaptive radiotherapy has emerged as a promising strategy to improve the precision of prostate cancer treatment by accounting for daily anatomical variations. Recent technological advances have enable…
Lucia F, Deiana L, Dupré PF, Chargari C.
Ovarian cancer recurs in a limited number of sites in a significant proportion of patients, raising interest in metastasis-directed therapy to delay systemic treatment escalation. Stereotactic body ra…
Kassardjian AA, Maraghechi B, Shi C, Ai H et al.
Purpose/objectivesOptimal implementation of gadoxetate disodium injection (GDI) in liver-directed MR-guided online adaptive radiotherapy (MRgART) remains poorly characterized. Herein, we evaluated the…
Oar A, Kneebone A, Sjoquist KM, Espinoza D et al.
BackgroundPancreatic ductal adenocarcinoma (PDAC) has poor outcomes and high rates of locoregional recurrence. MASTERPLAN evaluated whether stereotactic body radiotherapy (SBRT) reduced locoregional r…
Brownstein J, Williams T, Xu-Welliver M, Sebastian N et al.
IntroductionTumor hypoxia has been recognized as a barrier to effective radiotherapy. Preclinical work identified the FDA approved smooth muscle relaxant papaverine (PPV) as having an "off target" act…
Gao Y, Hsu E, Pham D, Skinner L et al.
PurposeConventional liver stereotactic ablative radiotherapy (SABR) typically requires a CT simulation visit followed by multiple treatment fractions, which can increase patient burden and limit acces…
Poeta S, Gulyban A, Paquier Z, Michel M et al.
PurposeTo quantify inter-physician contouring variability and evaluate its dosimetric impact in pancreatic ductal adenocarcinoma (PDAC) patients treated with daily online adaptive MR-guided stereotact…
Chuong MD, Beddar S.
Stereotactic body radiation therapy (SBRT), also referred to as stereotactic ablative radiotherapy (SABR), was pioneered at the Karolinska Institute in Sweden in the early 1990s, extending the princip…
Kenny K, Snyder KC, Huang Y, Vu K.
Ethos Intelligent Optimization Engine version 2 (IOE v2) generates automated treatment plans using user-defined templates that may not fully account for patient-specific anatomy. This retrospective st…
Niu L, Zhu L, Zhang Q, Bai Y et al.
Comparative evidence for hepatic resection and stereotactic body radiotherapy (SBRT) in breast cancer liver oligometastases remains limited. We compared survival, progression, and recovery after these…
Cheng K, Zhang C, Liu J, Xu H et al.
PurposeThe prognosis for metastatic pancreatic ductal adenocarcinoma (mPDAC) remains dismal. In this multicenter, single-arm, phase II study, we evaluated the combination of serplulimab, gemcitabine p…
Gjesdal BJ, Adida S, Taori S, Zureick AH et al.
PurposeElderly patients with spinal metastases are often considered poor candidates for aggressive local therapy, due in part to medical comorbidity and limited evidence to guide treatment selection. …
Hannan R, Lin L, Assadi R, Pop LM et al.
ImportanceRenal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus is associated with substantial perioperative risk and frequent recurrence despite nephrectomy and thrombectomy. No est…
Kamada M, Sasaki M, Nakaguchi Y, Kamomae T et al.
Feasibility dose-volume histogram (FDVH) analysis estimates patient-specific organ-at-risk dose-reduction feasibility, but the interpretation of FDVH-derived f-values in lung stereotactic body radioth…
Ojo O, Gill K, Huang B, Gui B et al.
BackgroundThe management of locally advanced periorbital skin tumors with orbital invasion is challenging. Orbital exenteration historically provides reliable local control but causes major functional…
Boutros M, Saad JP, Awad G, Hamdan KB et al.
Stereotactic body radiotherapy (SBRT) and conventional external beam radiotherapy (cEBRT) are widely used treatment options for the management of painful bone metastases. Randomized phase III trials h…
Kishan AU, Wilhalme H, Felix C, Enke J et al.
The phase 2 randomized LUNAR trial previously demonstrated that neoadjuvant ¹⁷⁷Lu-PNT2002 before stereotactic body radiotherapy (SBRT) significantly improved progression-free survival (PFS) in patient…
Sharon S, Qureshi MM, Keohan S, Luk S et al.
BackgroundStereotactic body radiotherapy (SBRT) is used for reirradiation in recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC), but prognostic factors remain unclear.MethodsWe r…
Yoo GS, Jeong JU, Lee JH, Ahn YC et al.
The therapeutic approach for oligometastatic non-small cell lung cancer (NSCLC) is rapidly shifting from palliative care to curative-intent strategies. This shift is largely driven by the integration …
Zhao Y, Wang S, He L, Shen X et al.
BackgroundStereotactic body radiotherapy (SBRT) combined with lenvatinib and tislelizumab has shown potential activity in advanced hepatocellular carcinoma (HCC), but early treatment failure (ETF) rem…
Smyczyńska U, Nowicka Z, Doyle P, Kang H et al.
IntroductionUrinary toxicities are common following prostate radiotherapy and can impair quality of life. New biomarkers are needed that can predict the risk of urinary toxicity following MRI guided s…
Katano A, Yamashita H.
BackgroundStereotactic body radiotherapy has become an established treatment option for localised prostate cancer. However, real-world evidence from routine clinical practice remains limited, particul…
Chmura SJ, Winter KA, Woodward WA, Borges VF et al.
PurposeMetastasis-directed therapy is increasingly used for oligometastatic breast cancer, despite its uncertain benefit during first-line systemic therapy. We evaluated whether metastasis-directed ab…
Sahin S, Ceylan C, Göksel EO, Özen Z.
This study aimed to characterize the response and inter-system consistency of a high-resolution myQA SRS detector used for patient-specific quality assurance (PSQA) across different configurations of …
Lichtman-Mikol S, Lang JM, Nagar H, Zuhour R et al.
IntroductionProstate cancer (PCa) is the most commonly diagnosed cancer in men worldwide. A rising proportion of men present with de novo metastatic disease, a state associated with poor survival outc…
Lilly DT, Chao ST, Angelov L.
Study designNarrative review.ObjectivesTo evaluate the current data related to radiation treatment for cervical spine tumors and how this impacts surgical strategies, emerging technologies, and the ef…
Egan D, Mohammadi F, Brotherton L, Ormiston W et al.
BackgroundStereotactic ablative body radiotherapy (SABR) shows promise as curative therapy for early-stage hepatocellular carcinoma (HCC). We retrospectively assessed the efficacy of SABR and microwav…
Chen P, Liu P, Cong X, Gao Y et al.
ObjectiveStereotactic body radiotherapy with a simultaneous integrated boost (SBRT-SIB) for locally advanced pancreatic cancer (LAPC) is constrained by the proximity of serial gastrointestinal organs …
Franzese C, Perrino M, Cordua N, Vincenzo F et al.
PurposeThe promising results of stereotactic body radiation therapy (SBRT) in achieving local control in various primary tumors and metastatic sites have prompted evaluation of its association with ou…
Ito K, Nakajima Y, Ogawa H, Furusawa A et al.
PurposeAlthough stereotactic body radiotherapy (SBRT) boost represents a promising treatment option for patients with locally advanced cervical cancer who were considered unsuitable for brachytherapy,…
Li J, Zhou N, Lu S, Yang X et al.
IntroductionImmunotherapy in combination with chemotherapy has been recommended as the first-line treatment of driver gene-negative advanced non-small cell lung cancer (NSCLC), but the efficacy is red…
Gevorkyan GS, Zhu L, Tegtmeier RC, Santos Toesca D et al.
BackgroundDose-guided adaptive fractionation (DGAF) was proposed as a simpler alternative of adaptive radiation therapy, using organ variation simulation for proof of concept. However, its dosimetric …
Cuccia F, Franzese C, Dubash S, Dionisi V et al.
Single-fraction stereotactic body radiotherapy (SF-SBRT) represents one of the most advanced frontiers in modern radiation oncology. While ultra-hypofractionation has entered everyday clinical practic…
Di S, VanGenderen B, Sonier M, Awotwi-Pratt J.
Stereotactic body radiotherapy (SBRT) for prostate cancer often uses high-energy photon beams, which can produce photoneutrons through interaction in the linac head, raising concerns regarding neutron…
Hartfelt PB, Bisgaard ALH, Ejlsmark MW, Bahij R et al.
PurposeThis prospective single-center cohort study evaluated outcomes and toxicity after ablative stereotactic magnetic resonance imaging (MRI)-guided adaptive radiation therapy (SMART) in patients wi…
Tamura M, Nishimura Y, Matsuura T, Inosaka Y et al.
BackgroundA new preconfigured CyberKnife system was introduced to improve the SRS/SBRT commissioning efficiency. The vendor provides a reference beam data set, termed "beam data model (BDM)", and reco…
Zafar AJ, Yang X, Dutta SW, Wang Y et al.
ObjectiveHighly conformal proton stereotactic body radiation therapy (SBRT) remains vulnerable to respiratory interplay, and standard mitigation techniques are either patient-dependent or enlarge the …
St-Aubin J, Gutierrez A, Kinsey E, Stambaugh C et al.
This work of fiction is part of a case study series developed by the medical physics leadership academy (MPLA). It is designed to generate discussion of the managerial and leadership challenges medica…
Gui B, Sekar J, Locke M, Saha S et al.
Purpose/objectivesRecurrent and metastatic non-anaplastic thyroid cancer has traditionally been considered relatively radioresistant. We evaluated whether anatomic site or histology risk group better …
Matsuda M, Komiyama T, Marino K, Chen Z et al.
PurposeStereotactic body radiotherapy (SBRT) is a well-established treatment for early stage non-small cell lung cancer (NSCLC); however, outcomes beyond 10 years remain poorly defined. We aimed to ev…
Cuccia F, Campione M, Mortellaro G, Figlia V et al.
AimsFor patients with unresectable stage III non-small cell lung cancer (NSCLC) ineligible for concurrent chemo-radiation (cCRT), stereotactic body radiotherapy (SBRT) may provide a favorable efficacy…
Zafra-Martin J, Onieva JL, Jimenez-Rodriguez H, Martinez B et al.
Stereotactic ablative radiotherapy (SABR) may extend the clinical benefit of immune checkpoint inhibitors (ICI) in patients with oligoprogressive disease. However, individual benefit varies, and valid…
Paunoiu A, Fritsak M, Gabryś HS, Christ SM et al.
Background and purposeMagnetic resonance-guided radiotherapy (MRgRT) offers high-quality soft tissue contrast and treatment monitoring, supporting longitudinal radiomics analysis. We investigated trea…
Aguirre-Meneses KA, Baker S, Callueng JM, Chng N et al.
ObjectivesOptimal dose fractionation of stereotactic ablative radiotherapy (SABR) in early-stage non-small cell lung cancer (NSCLC) remains unclear. This population-based study compares outcomes and t…
Oka A, Yamashita H, Miki Y, Sawayanagi S et al.
This study evaluated the clinical outcomes and safety of risk-adapted stereotactic body radiotherapy (SBRT) using non-standard fractionation schedules for lung tumors adjacent to organs at risk (OARs)…
Chou KN, Park DJ, Hori YS, Persad AR et al.
ObjectiveStereotactic body radiotherapy (SBRT) has emerged as a highly effective, noninvasive treatment for spinal bone metastases (SBMs). However, long-term outcomes of primary SBRT and the comparati…
Risumlund SL, Stick LB, Appelt A, Vogelius IR et al.
BackgroundLocal therapies can achieve durable disease control in selected patients with oligometastatic colorectal liver metastases. Microwave ablation (MWA) is widely used, whereas stereotactic body …
Sud A, Huang J, Hart GR, Kim J et al.
Background/Objectives: Stereotactic body radiation therapy (SBRT), often delivered in 3-5 fractions, is a highly effective treatment strategy for early-stage non-small cell lung cancer (NSCLC) in medi…
Aguirre-Meneses KA, Owen J, Mou B.
Intramedullary spinal cord metastasis (ISCM) is an uncommon and challenging clinical entity with no established consensus regarding its optimal management. A 37-year-old female presented with left-sid…
Moncrief OG, Warren EG, Larramendi LZ, Wang CJ et al.
Daily anatomical variations can compromise dosimetric plan quality in kidney stereotactic ablative radiotherapy (SABR). The purpose of this study is twofold: (1) To characterize the impact of daily an…
Viani GA, Hamamura AC, Arruda CV, Cardoso CE et al.
ObjectiveStereotactic ablative radiotherapy (SABR) is increasingly used for oligometastatic breast cancer, but it is unclear in whom local ablation translates into systemic benefit. We compared de nov…
Yamashita H, Sugahara D, Sawayanagi S, Nozawa Y et al.
This study aimed to determine whether 36.25 Gy was inferior to 40 Gy in terms of prostate-specific antigen (PSA) recurrence following stereotactic body radiation therapy (SBRT) for prostate cancer. We…
Bayram Y, Saynak M, Aksoy Y, Güre M et al.
Stereotactic body radiotherapy (SBRT) for liver metastases requires accurate dose calculation. The Monte Carlo (MC) algorithm in the Monaco treatment planning system (TPS) provides high dose-calculati…
Hoeksema WF, Belderbos J, Dieleman EMT, van Doorn-Wink K et al.
PurposeSeveral studies show associations between cardiac radiation dose and cardiac morbidity or overall survival. To evaluate cardiac toxicity of radiation therapy in the absence of another cardiotox…
Mao Q, Yu Y, Fang Y, Zhu S et al.
Osunkwor O, Ndlovu A, Teboh R.
Mao Q, Yu Y, Fang Y, Zhu S et al.
This review aims to systematically summarize the mechanisms of action, clinical evolution, and application prospects of radiotherapy in neoadjuvant therapy for stage III non-small cell lung cancer. Fo…
Mizumatsu S, Tsukushi S.
Showing the 60 most recent of 426 papers in this topic.Browse every paper →
Request brochure
Tell us who you are and we’ll send the full product brochure to your institutional email after a quick review. We respond within one working day (Mon–Fri, 9:30–18:30 IST).
A Saxsons sales engineer will review your request and send the brochure to your institutional email within one working day. You may receive a verification call before processing.
